Tissue-engineered heart valves (TEHVs) are a promising treatment for
valvular heart disease, although their application is limited by high flow shear stress (FSS).
Melatonin has a wide range of physiological functions and is currently under clinical investigation for expanded applications; moreover, extensive protective effects on the cardiovascular system have been reported. In this study, we investigated the protection conferred by
melatonin supplementation against FSS-induced injury in bone marrow mesenchymal stem cells (BMSCs) and elucidated the potential mechanism in this process.
Melatonin markedly reduced BMSC apoptotic death in a concentration-dependent manner while increasing the levels of
transforming growth factor β (TGF-β),
basic fibroblast growth factor (bFGF),
vascular endothelial growth factor (
VEGF),
platelet-derived growth factor (PDGF) and
B-cell lymphoma 2 (Bcl2), and decreasing those of
Bcl-2-associated X protein (Bax), p53 upregulated modulator of apoptosis (PUMA), and
caspase 3. Notably,
melatonin exerted its protective effects by upregulating the phosphorylation of
adenosine monophosphate-activated
protein kinase (AMPK), which promotes
acetyl-CoA carboxylase (ACC) phosphorylation. Further molecular experiments revealed that
luzindole, a nonselective antagonist of
melatonin receptors, blocked the anti-FSS injury (anti-FSSI) effects of
melatonin. Inhibition of AMPK by Compound C also counteracted the protective effects of
melatonin, suggesting that
melatonin reverses FSSI in BMSCs through the AMPK-dependent pathway. Overall, our findings indicate that
melatonin contributes to the amelioration of FSS-induced BMSC injury by activating
melatonin receptors and AMPK/ACC signaling. Our findings may provide a basis for the design of more effective strategies that promote the use of TEHCs in patients.